Fibroblast Growth Factor 21 Agonists for the Treatment of Patients With Metabolic Dysfunction-Associated Steatohepatitis.
作者信息
Newsome Philip
机构信息
Director of Roger Williams Institute of Liver Studies Professor of Hepatology King's College London Honorary Consultant Hepatologist King's College Hospital Director of King's Health Partners Centre for Translational Medicine London, United Kingdom.
出版信息
Gastroenterol Hepatol (N Y). 2025 Aug;21(8):489-491.
Abstract
摘要
相似文献
1
Fibroblast Growth Factor 21 Agonists for the Treatment of Patients With Metabolic Dysfunction-Associated Steatohepatitis.
Gastroenterol Hepatol (N Y). 2025 Aug;21(8):489-491.
2
NASH-CHECK patient-reported outcome instrument: evaluation of content and face validity for patients with metabolic dysfunction-associated steatohepatitis and compensated cirrhosis.
J Patient Rep Outcomes. 2025 Jul 1;9(1):76. doi: 10.1186/s41687-025-00881-6.
3
Efficacy and Safety of Fibroblast Growth Factor-21 Analogs for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis.
Clin Pharmacol Ther. 2024 Jul;116(1):72-81. doi: 10.1002/cpt.3278. Epub 2024 Apr 26.
4
Incretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease.
Curr Pharm Des. 2025 Jul 9. doi: 10.2174/0113816128378484250619080753.
5
Prospects of Late-Stage Development Agents in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Clin Mol Hepatol. 2025 Aug 4. doi: 10.3350/cmh.2025.0337.
6
Fibroblast growth factor 15 overexpression and combined peroxisome proliferator-activated receptor α activation attenuates metabolic dysfunction-associated steatohepatitis progression in mice.
Drug Metab Dispos. 2025 Sep;53(9):100128. doi: 10.1016/j.dmd.2025.100128. Epub 2025 Jul 25.
7
New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024.
Acta Pharmacol Sin. 2025 May;46(5):1145-1155. doi: 10.1038/s41401-024-01466-7. Epub 2025 Jan 27.
9
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
N Engl J Med. 2025 Jun 5;392(21):2089-2099. doi: 10.1056/NEJMoa2413258. Epub 2025 Apr 30.
10
Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway.
J Hepatol. 2025 Feb 11. doi: 10.1016/j.jhep.2025.02.003.
本文引用的文献
1
Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.
J Clin Invest. 2025 Jul 1;135(13). doi: 10.1172/JCI186425.
2
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial.
Lancet Gastroenterol Hepatol. 2025 Aug;10(8):734-745. doi: 10.1016/S2468-1253(25)00067-6. Epub 2025 Jun 6.
3
FGF21 reverses MASH through coordinated actions on the CNS and liver.
Cell Metab. 2025 Jul 1;37(7):1515-1529.e6. doi: 10.1016/j.cmet.2025.04.014. Epub 2025 May 13.
4
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.
N Engl J Med. 2025 Jun 26;392(24):2413-2424. doi: 10.1056/NEJMoa2502242. Epub 2025 May 9.
5
Efficacy and Safety of Fibroblast Growth Factor 21 Analogues for Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis.
Ann Nutr Metab. 2025;81(1):51-60. doi: 10.1159/000541583. Epub 2024 Oct 3.
6
FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond.
J Hepatol. 2024 Sep;81(3):562-576. doi: 10.1016/j.jhep.2024.04.034. Epub 2024 May 4.
7
Efficacy and Safety of Fibroblast Growth Factor-21 Analogs for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis.
Clin Pharmacol Ther. 2024 Jul;116(1):72-81. doi: 10.1002/cpt.3278. Epub 2024 Apr 26.
8
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study.
Clin Gastroenterol Hepatol. 2025 Jan;23(1):103-113. doi: 10.1016/j.cgh.2024.02.022. Epub 2024 Mar 4.
9
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
Lancet Gastroenterol Hepatol. 2023 Dec;8(12):1080-1093. doi: 10.1016/S2468-1253(23)00272-8. Epub 2023 Oct 3.
10
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.
N Engl J Med. 2023 Sep 14;389(11):998-1008. doi: 10.1056/NEJMoa2304286. Epub 2023 Jun 24.
Zotero 插件